Drug Trial Radar · NCT05630612
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
32
Actual
Start
Dec 8, 2022
Primary completion
Jul 18, 2024
Study completion Sep 1, 2027
Sponsor
- Lead sponsor
- University of EdinburghAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Travere Therapeutics, Inc.
- First posted
- Nov 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ANCA-associated vasculitis is an autoimmune disease that causes damage to blood vessels. This leads to organ damage with the number of organs affected and the severity of damage varying significantly between patients. Vasculitis patients also have a very high risk of heart attacks and strokes, called cardiovascular disease. A chemical called 'endothelin', produced by the blood vessels, causes vessels to stiffen and raises blood pressure and this associates with cardiovascular risk. The investigators have previously shown that by blocking the effects of endothelin you reduce vessel stiffness, lower blood pressure and improve vessel function. However, these studies only blocked endothelin for a few hours. Now, the investigators would like to see if it is possible to maintain these benefits by blocking endothelin for longer. Sparsentan is a tablet that blocks endothelin and lowers blood pressure. The investigators plan to give sparsentan to patients with vasculitis for 6 weeks. To determine if any beneficial effects of sparsentan are due to blood pressure lowering the investigators will give another group of vasculitis patients a tablet called irbesartan which lowers blood pressure but does not block endothelin. The investigators will compare the results between the two groups.
Conditions
- ANCA Associated Vasculitis
- Cardiovascular Diseases
- Kidney Diseases
Interventions
SparsentanDrug
6 weeks of treatment with sparsentan or irbesartan. This will be administered in a double-blind fashion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Forearm blood flowTime frame: Comparing baseline to after 6 weeks of intervention.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for Cardiovascular Science, Queen's Medical Research Institute, 47 Little France Crescent
Edinburgh, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.